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To the Editor
We evaluated the analytical performance of the immuno-
enzymometric assay for the cTnI, named ST AIA-PACK cTnI 3rd-Gen,
using the automated AIA-2000 platform (Tosoh Corporation, Tokyo,
Japan). This method is a two-site immunoenzymometric assay, which
uses a combination of twomonoclonal antibodies, respectively directed
to 41–49 and 87–91 amino acids of the cTnI peptide chain, and the ter-
nary troponin ITC complex as a calibration antigen [1].
Blood samples from patients with cardiac diseases or healthy subjects
were collected in polypropylene tubes without or with lithium heparin.
Sampleswere then rapidly centrifuged at 3000 ×g for 10 min andplasma
was then analyzed within 1 h or alternatively, stored at−80 °C.
The limits of blank (LoB) and detection (LoD) for cTnI assay were
determined according to the CLSI EP17-A protocol [2]; the calculated
LoB and LoD values were 3.5 ng/L and 8.7 ng/L, respectively. The assay
reproducibility was evaluated in accordance with the CLSI EP5-A2 pro-
tocol [3] by repeatedly measuring 3 heparinized plasma samples for
consecutive 20 working days with different cTnI concentrations; the
results are reported in Table 1. The between-runs imprecision proﬁle
was performed by repeatedly measuring in 20 different runs 10 hepa-
rinized blood samples collected from healthy subjects and patients
with acute myocardial infarction (mean cTnI concentrations from 13
to 17,782 ng/L). The calculated limits of quantitation (LoQ) at 20% CV
and 10% CV were 30 and 100 ng/L of cTnI, respectively.
We also evaluatedwhether themeasurement in heparinized plasma
and serum samples actually gives similar results. A very close linear re-
lationship was found between the cTnI values measured in 105 serum
(X-axis) and heparinized plasma (Y-axis) samples of healthy subjects
and patients with cardiac diseases (cTnI plasma=3.10+0.95 cTnI
serum; R=0.999). A very close linear regression (R=0.991, n=521,
y=58.3+0.602x) was found between the cTnI values measured with
the Tosoh method (Y-axis) and Access AccuTnI method (X-axis),
using the UniCell DxI 800 platform (Beckman Coulter, Inc., Fullerton,
USA) in 521 heparinized plasma samples of healthy subjects and cardiac
patients (Supplemental File 1). However, Tosoh method showed a mean
negative bias (i.e., underestimation) of cTnI value compared to Beckman–
Coulter by −30.2% (p=0.0024 by Wilcoxon signed rank test). A close
correlation (R=0.938, n=521, y=−1067+11.6x) was also found
between the cTnI and cTnT values, measured with Tosoh method
(X-axis) and Troponin T-hs method (Y-axis), using the automated
Cobas e411 platform (Roche Diagnostics, Germany) (Supplemental
File 2).
The distribution of cTnI values, measured by the Tosoh method,
was evaluated in 452 healthy individuals (M 326, F 126; mean age
45.6 years, median 45 years, interquartile range 33.0–58.0 years,
range 17–76 years), recruited from laboratory staff, blood donors, or
voluntary subjects, included in screening programs for preventive
medicine. The presence of cardiac or systemic acute or chronic dis-
eases was excluded in all subjects by history, accurate clinical exam-
ination, ECG, cardiac imaging, and laboratory tests. Furthermore, all
subjects denied the use of drugs for at least two weeks before the
sample collection for cTnI assay. The informed consent was obtained
by all subjects enrolled in the study and the screening programs were
approved by the local ethical committee. The calculated 99th percentile
of the cTnI values was 33 ng/L (median 9.0 ng/L, range 0–44 ng/L). The
percentages of healthy population with values equal or less than LOB
(3.5 ng/L) and LOD (8.7 ng/L) valueswere 15.7% and 49.8%, respectively.
Quality speciﬁcations [4,5] for troponin measurement recommend
an assay imprecision ≤10% CV for the values corresponding to the
99th percentile of reference population. Use of troponin assays with
intermediate imprecision (from 10% to 20% CV) at the 99th percentile,
however, does not lead to signiﬁcant patient misclassiﬁcation, when
interpreting serial troponin results [4,5].
Compared to previous second-generation AIA-Pack assay [4], the
third-generation AIA-Pack assay for cTnI showed an improved analyt-
ical sensitivity and reproducibility, especially at very low cTnI concen-
trations. Indeed, the LoD and 10% LoQ values of the second-generation
assay, as reported in a previous study [1], were 38 ng/L and130 ng/L, re-
spectively,while the corresponding values of the third-generation assay,
as assessed in the present study, were 8.7 ng/L and 100 ng/L. This im-
proved imprecision at lower cTnI concentrations allows the measure-
ment of the 99th percentile of reference population (i.e., 33 ng/L) with
an imprecision less than 20%, as well as the detection with conﬁdence
(measured values above the LoD) of cTnI circulating levels in more
than half of normal subjects. These analytical performances suggest
that the third-generation AIA-Pack Tosoh assay for cTnI should be con-
sidered as “clinically acceptable”, according to the scorecard proposed
by Apple [4].
The third-generation AIA-Pack Tosoh assay for cTnI showed a very
close agreement throughout all the working range with the Access
AccuTnI Beckam–Coulter method, used for the routine measurement
of cTnI in the Authors' laboratory (Supplemental File 1). Moreover, a
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Table 1
Evaluation of assay reproducibility according to the CLSI EP5-A2 protocol.
Sample n Mean cTnI concentration (ng/L) Within-run CV (%) Total CV (%)
A 20 22 19.62 35.46
B 20 52 9.14 18.42
C 20 119 4.00 6.50
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close agreement was also demonstrated between the cTnI measured
by Tosoh methods and those of cTnT measured with ECLIA Roche
method (Supplemental File 2). These data suggest that the third-
generation AIA-Pack assay is suitable for the clinical evaluation of
patients with cardiac diseases.
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